These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756). Deng X; S Gray N Expert Opin Ther Pat; 2012 Jun; 22(6):709-13. PubMed ID: 22607035 [TBL] [Abstract][Full Text] [Related]
4. Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors. Estrada AA; Sweeney ZK J Med Chem; 2015 Sep; 58(17):6733-46. PubMed ID: 25915084 [TBL] [Abstract][Full Text] [Related]
6. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721 [TBL] [Abstract][Full Text] [Related]
7. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184 [TBL] [Abstract][Full Text] [Related]
14. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors. Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068 [TBL] [Abstract][Full Text] [Related]
15. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein. Yun H; Heo HY; Kim HH; DooKim N; Seol W Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311 [TBL] [Abstract][Full Text] [Related]
16. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Covy JP; Giasson BI Biochem Biophys Res Commun; 2009 Jan; 378(3):473-7. PubMed ID: 19027715 [TBL] [Abstract][Full Text] [Related]
17. Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date. Morez M; Lara Ordóñez AJ; Melnyk P; Liberelle M; Lebègue N; Taymans JM Expert Opin Ther Pat; 2024 Sep; 34(9):773-788. PubMed ID: 39023243 [TBL] [Abstract][Full Text] [Related]
18. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease. Gilligan PJ Curr Top Med Chem; 2015; 15(10):927-38. PubMed ID: 25832719 [TBL] [Abstract][Full Text] [Related]